Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab-Reference-Cited by-同舟云学术

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

Published:2010-12-08 Issue:1 Volume:69 Page:83-89
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol.

Author:

Gunnarsson Martin,Malmeström Clas,Axelsson Markus,Sundström Peter,Dahle Charlotte,Vrethem Magnus,Olsson Tomas,Piehl Fredrik,Norgren Niklas,Rosengren Lars,Svenningsson Anders,Lycke Jan

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Reference29 articles.

1. Axonal transection in the lesions of multiple sclerosis;Trapp;N Engl J Med,1998

2. Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis;Pascual;Neurology,2007

3. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis;Filippi;Brain,2003

4. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability;De Stefano;Arch Neurol,2002

5. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis;Teunissen;Neurology,2009

Cited by 304 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fluid biomarkers in multiple sclerosis: from current to future applications;The Lancet Regional Health - Europe;2024-09

2. J-shaped relationship of serum neurofilament light chain with urinary albumin excretion in US adults: NHANES 2013–2014;Renal Failure;2024-08-21

3. Assessment of ocrelizumab impact on neurofilament levels in multiple sclerosis patients;Revista Romana de Medicina de Laborator;2024-07-01

4. Glial fibrillary acidic protein and neurofilament light chain as biomarkers in pediatric multiple sclerosis;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2024-07

5. Real-World Study of Serum Neurofilament Light Chain Levels in Ocrelizumab-Treated People with Relapsing Multiple Sclerosis;Journal of Personalized Medicine;2024-06-27